Tags

Type your tag names separated by a space and hit enter

Ulerythema ophryogenes: updates and insights.
Cutis 2014; 93(2):83-7C

Abstract

Ulerythema ophryogenes is a rare cutaneous atrophic disorder that occasionally is associated with Noonan syndrome, de Lange syndrome, Rubinstein-Taybi syndrome, and cardiofaciocutaneous (CFC) syndrome. Often presenting in pediatric patients, the pathogenesis of ulerythema ophryogenes remains unclear, though several genetic causes have been suggested. Treatment recommendations remain anecdotal, but clearance has been noted as the patient ages. Although topical agents have been the mainstay of therapy, recent advancement in laser intervention for treatment of ulerythema ophryogenes is promising.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableDepartment of Dermatology, Rutgers New Jersey Medical School, Medical Science Building, H-576, Newark, NJ 07103, USA. roschwar@cal.berkeley.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24605344

Citation

Morton, Christopher M., et al. "Ulerythema Ophryogenes: Updates and Insights." Cutis, vol. 93, no. 2, 2014, pp. 83-7.
Morton CM, Bhate C, Janniger CK, et al. Ulerythema ophryogenes: updates and insights. Cutis. 2014;93(2):83-7.
Morton, C. M., Bhate, C., Janniger, C. K., & Schwartz, R. A. (2014). Ulerythema ophryogenes: updates and insights. Cutis, 93(2), pp. 83-7.
Morton CM, et al. Ulerythema Ophryogenes: Updates and Insights. Cutis. 2014;93(2):83-7. PubMed PMID: 24605344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ulerythema ophryogenes: updates and insights. AU - Morton,Christopher M, AU - Bhate,Chinmoy, AU - Janniger,Camila K, AU - Schwartz,Robert A, PY - 2014/3/8/entrez PY - 2014/3/8/pubmed PY - 2014/10/30/medline SP - 83 EP - 7 JF - Cutis JO - Cutis VL - 93 IS - 2 N2 - Ulerythema ophryogenes is a rare cutaneous atrophic disorder that occasionally is associated with Noonan syndrome, de Lange syndrome, Rubinstein-Taybi syndrome, and cardiofaciocutaneous (CFC) syndrome. Often presenting in pediatric patients, the pathogenesis of ulerythema ophryogenes remains unclear, though several genetic causes have been suggested. Treatment recommendations remain anecdotal, but clearance has been noted as the patient ages. Although topical agents have been the mainstay of therapy, recent advancement in laser intervention for treatment of ulerythema ophryogenes is promising. SN - 2326-6929 UR - https://www.unboundmedicine.com/medline/citation/24605344/Ulerythema_ophryogenes:_updates_and_insights L2 - http://www.cutis.com/the-publication/past-issues-single-view/ulerythema-ophryogenes-updates-and-insights/2de6f3583c85cd1ccf40aad14a2ef178.html DB - PRIME DP - Unbound Medicine ER -